S&P Futures
4,160.50+5.00(+0.12%)Dow Futures
33,976.00+18.00(+0.05%)Nasdaq Futures
13,930.50+33.25(+0.24%)
Inventiva S.A. (IVEVF)
Chart Events
Performance Outlook
| Previous Close | 10.84 |
| Open | 10.84 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 10.84 - 10.84 |
| 52 Week Range | 2.62 - 15.40 |
| Volume | 100 |
| Avg. Volume | 0 |
| Market Cap | 522.494M |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
Daix (France), April 19, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA) is pleased to announce the appointment of Martine Zimmermann to its Board of Directors as an independent director. Inventiva’s Board of Directors appointed Martine Zimmerman to replace Nawal Ouzren, who resigned from the Board of Directors in order to focus on the growth of Sensorion. Martine Zimmerman's appointment will be submitted to the shareholders for ratification at the next general shareholders meeting. With over 25 years of global experience in the pharmaceutical industry, Martine Zimmermann has been the Senior Vice President and Head of Global Regulatory Affairs of Alexion Pharma International since June 2016. Throughout her career, she has acquired extensive expertise as Regulatory Affairs Executive in both small and large pharmaceutical groups, holding senior roles in the United States, Europe and Asia-Pacific. Martine Zimmermann has worked across all phases of drug development within several therapeutic areas, interacting with relevant regulatory authorities in key markets, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). She is also an active member of several life-sciences trade associations and has been a member of the Board of Directors of U.S.-based Caelum Biosciences since 2019. Frédéric Cren, Chairman, CEO and co-founder of Inventiva, commented: “I am very pleased to welcome Martine Zimmermann to Inventiva’s Board of Directors. Her deep knowledge of the industry and her international experience, paired with her expertise in regulatory matters across geographies, will be a great addition for the Company. At the same time, I would like to warmly thank Nawal Ouzren on behalf of the Board for her valuable contribution to Inventiva over the last two years and wish her all the best going forward.” About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts InventivaFrédéric CrenChairman & CEOinfo@inventivapharma.com+33 3 80 44 75 00Brunswick GroupYannick Tetzlaff / Tristan Roquet Montegon / Aude LepreuxMedia relationsinventiva@brunswickgroup.com+33 1 53 96 83 83Westwicke, an ICR CompanyPatricia L. BankInvestor relationspatti.bank@westwicke.com+1 415 513-1284 Important Notice This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and that any new appointments may not be ratified by the shareholders. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 2021 as well as the full-year financial report for the year ended December 31, 2020 for additional information in relation to such factors, risks and uncertainties. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - Appointment Martine Zimmermann - 19 04 2021 - EN - VF
- GlobeNewswire
Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021
Daix (France), April 19, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the results of the votes of its Combined Shareholders’ Meeting on April 16, 2021. The Combined Shareholders' Meeting was held under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva, at the Company's registered office, 50, rue de Dijon - 21121 Daix, France, virtually, without the physical presence of the shareholders and other persons entitled to attend, in accordance with the derogatory measures relating to the adaptation of the rules of meeting and deliberation of shareholders' meetings taken by the French authorities because of the COVID-19 pandemic. All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 24th resolution which would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company. Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2020 Universal Registration Document (Part 3.5.1, pages 141 and seq.). Information on the results of the votes is detailed below: Total number of shares composing the share capital: 38 630 261Total number of shares with voting rights: 38 585 566 Ordinary partExtraordinary partShareholdersSharesVotesShareholdersSharesVotes Shareholders present000000 Proxy to third parties000000 Proxy to the Chairman2212 652 1732 673 2832212 652 1732 673 283 Mail votes11327 197 71938 630 39711327 197 71938 630 397 TOTAL33429 849 89241 303 68033429 849 89241 303 680 Quorum77.36%77.36% ResolutionsState of adoptionNumber of represented sharesProportion of represented share capital(%)Total number of votes cast ForAgainstAbstention Number of votes in % of votes castNumber of votesin % of votes castNumber of votesin % of the total voting rightsResolution 1 - OGMAdopted29 849 89277.27%41 303 31541 303 183>99.99%1320.00%3650.00%Resolution 2 - OGMAdopted29 849 89277.27%41 303 35841 303 183>99.99%1750.00%3220.00%Resolution 3 - OGMAdopted29 849 89277.27%41 303 35241 303 190>99.99%1620.00%3280.00%Resolution 4 - OGMAdopted29 849 89277.27%41 303 17541 303 043>99.99%1320.00%5050.00%Resolution 5 - OGMAdopted29 849 89277.27%41 300 74739 439 44995.49%1 861 2984.51%2 9330.01%Resolution 6 - OGMAdopted29 849 89277.27%41 300 73039 439 38395.49%1 861 3474.51%2 9500.01%Resolution 7 - OGMAdopted29 849 89277.27%41 300 78841 103 69199.52%197 0970.48%2 8920.01%Resolution 8 - OGMAdopted29 849 89277.27%41 301 84040 440 27897.91%861 5622.09%1 8400.00%Resolution 9 - OGMAdopted29 849 89277.27%41 301 84040 440 32497.91%861 5162.09%1 8400.00%Resolution 10 - OGMAdopted29 849 89277.27%41 301 99041 292 73899.98%9 2520.02%1 6900.00%Resolution 11 - OGMAdopted29 849 89277.27%41 302 85141 302 429>99.99%4220.00%8290.00%Resolution 12 - OGMAdopted29 849 89277.27%41 302 82041 302 530>99.99%2900.00%8600.00%Resolution 13 - OGMAdopted29 849 89277.27%41 302 78341 302 543>99.99%2400.00%8970.00%Resolution 14 - OGMAdopted29 849 89277.27%41 303 30839 435 34495.48%1 867 9644.52%3720.00%Resolution 15 - EGMAdopted29 849 89277.27%41 302 54841 105 59199.52%196 9570.48%1 1320.00%Resolution 16 - EGMAdopted29 849 89277.27%41 302 50239 440 82295.49%1 861 6804.51%1 1780.00%Resolution 17 - EGMAdopted29 849 89277.27%41 302 55239 437 78895.49%1 864 7644.51%1 1280.00%Resolution 18 - EGMAdopted29 849 89277.27%41 249 71639 384 92295.48%1 864 7944.52%53 9640.11%Resolution 19 - EGMAdopted29 849 89277.27%41 249 66639 385 45695.48%1 864 2104.52%54 0140.11%Resolution 20 - EGMAdopted29 849 89277.27%41 249 68639 485 59995.72%1 764 0874.28%53 9940.11%Resolution 21 - EGMAdopted29 849 89277.27%41 249 64439 386 42095.48%1 863 2244.52%54 0360.11%Resolution 22 - EGMAdopted29 849 89277.27%41 302 48039 440 26595.49%1 862 2154.51%1 2000.00%Resolution 23 - EGMAdopted29 849 89277.27%41 302 58439 432 70295.47%1 869 8824.53%1 0960.00%Resolution 24 - EGMRejected29 849 89277.27%41 298 55514 132 29034.22%27 166 26565.78%5 1250.01%Resolution 25 - EGMAdopted29 849 89277.27%41 298 57541 297 126>99.99%1 4490.00%5 1050.01%Resolution 26 - EGMAdopted29 849 89277.27%41 297 52939 436 32195.49%1 861 2084.51%6 1510.01%Resolution 27 - EGMAdopted29 849 89277.27%41 301 25139 439 03795.49%1 862 2144.51%2 4290.00%Resolution 28 - EGMAdopted29 849 89277.27%41 298 59039 435 39995.49%1 863 1914.51%5 0900.01%Resolution 29 - OGMAdopted29 849 89277.27%41 302 44541 301 162>99.99%1 2830.00%1 2350.00% About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Inventiva Frédéric Cren Chairman & CEO info@inventivapharma.com +33 3 80 44 75 00 Brunswick Group Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1 415 513 1284 Attachment Inventiva - PR - Résultats AG 2021 - EN - 19.04.2021
- GlobeNewswire
Inventiva's Combined Shareholders Meeting of April 16, 2021 - Availability of the preparatory documents and methods for participating and voting
Daix (France), March 25, 2021 – Given the current health context, in accordance with the provisions of Order no. 2020-321 of March 25, 2020 adapting the form of meeting and decision-making rules for shareholders meetings and governing bodies of legal entities during the COVID-19 pandemic, as prorogated by Decree no. 2021-255 of March 9, 2021, Inventiva informs its shareholders and the entire financial community of the decision, taken today by its Chairman and Chief Executive Officer, upon delegation of the Board of Directors pursuant to Article 7 of said Order, to hold the next Combined (Ordinary and Extraordinary) Shareholders Meeting virtually, with no shareholder physically present, at 2 pm (CET) on April 16, 2021, at the Company’s registered office. Availability of the preparatory documents Documents for the Shareholders Meeting will be sent out by email, upon request to the Company, or can be downloaded from the "Investors" / "Shareholder Meetings" section of its website at www.inventivapharma.com. Methods for participating Shareholders will be able to attend the live broadcast of the Shareholders Meeting using one of the two following options: Option #1 – Webcast: https://edge.media-server.com/mmc/p/rdr7tfxeOption #2 – Conference call: Numbers: France: +33 (0) 1 70 70 07 81Belgium: +32 (0) 2 793 3847Germany: +49 (0) 69 2222 2625Netherlands: +31 (0) 20 795 6614Switzerland: +41 (0) 44 580 7145United Kingdom: +44 (0) 207 192 8338United States: +1 646-741-3167 Access code: 8681244 After the event, a replay of the Shareholders Meeting will also be available in the "Investors" / "Shareholder Meetings" section of the Company’s website at www.inventivapharma.com. Methods for voting and submitting written questions Shareholders are invited to exercise their voting rights prior to the Shareholders Meeting, either by using the Internet-based Votaccess secure platform or by sending in their form-based voting instructions by mail, or by giving proxy. The proxies to third parties will be processed in accordance with Article 6 of Decree no. 2020-418 of April 10, 2020. The detailed modalities for voting are specified in the notice of the Shareholders Meeting brochure available in the "Investors" / "Shareholder Meetings" section of the Company’s website at www.inventivapharma.com and will also be included in the notice of meeting published in the French Bulletin of Legal Announcements (BALO). Since no shareholders will attend the meeting in person, it will not be possible to ask questions orally during the Shareholders Meeting. However, in order to encourage dialog, shareholders will have the opportunity to send their written questions to the Board of Directors no later than two business days ahead of the Shareholders Meeting, that is by Wednesday, April 14, 2021. They must be sent to the Company’s registered office by registered letter with return receipt requested. The questions must be accompanied by a certificate proving ownership of shares in the Company’s registered share accounts or in the bearer share accounts administered by third-party intermediaries, as listed in Article L. 211-3 of the French Monetary and Financial Code. The detailed modalities for submitting written questions prior to the Shareholders Meeting will also be laid down in the notice of the Shareholders Meeting, which will be published in the French Bulletin of Legal Announcements (BALO) and in the "Investors" / "Shareholder Meetings” section of the Company’s website at www.inventivapharma.com. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Inventiva Frédéric Cren Chairman & CEO info@inventivapharma.com +33 3 80 44 75 00 Brunswick Group Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1 415 513 1284 Attachment Inventiva - PR - AGM - Availability of the preparatory documents - 25 03 2021
